Literature DB >> 23670286

Immunohistochemical detection of SATB1 is independent of thyroid cancer differentiation.

Shigeyuki Murono1, Akira Tsuji, Kazuhira Endo, Satoru Kondo, Naohiro Wakisaka, Tomokazu Yoshizaki.   

Abstract

OBJECTIVES/HYPOTHESIS: The association of special AT-rich binding protein 1 (SATB1) with a poor prognosis in various cancers has been reported. However, this association is controversial. SATB1 expression in aggressive types of thyroid cancer has not been reported to date. STUDY
DESIGN: Retrospective.
METHODS: SATB1 expression was immunohistochemically investigated in 35 papillary thyroid cancers, one follicular thyroid cancer, six poorly differentiated thyroid cancers, and two anaplastic thyroid cancers.
RESULTS: SATB1 expression was observed in none of two anaplastic thyroid cancers, one of six poorly differentiated thyroid cancers, and nine of 36 well-differentiated thyroid cancers. SATB1 expression was not significantly associated with any high-risk group-related clinicopathologic factors in well-differentiated thyroid cancer. Survival was not associated with SATB1 expression.
CONCLUSIONS: SATB1 expression is independent of thyroid cancer differentiation, as well as high-risk-related factors. SATB1 may not play a role in the aggressiveness of thyroid cancer.
Copyright © 2013 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  SATB1; aggressiveness; differentiation; high-risk; thyroid cancer

Mesh:

Substances:

Year:  2013        PMID: 23670286     DOI: 10.1002/lary.23992

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  1 in total

1.  Expression of p16 and SATB1 in Invasive Ductal Breast Cancer - A Preliminary Study.

Authors:  Christopher Kobierzycki; Jedrzej Grzegrzolka; Natalia Glatzel-Plucinska; Aleksandra Piotrowska; Andrzej Wojnar; Beata Smolarz; Hanna Romanowicz; Piotr Dziegiel
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.